Disclaimer:

Disclaimer: The blog posts and comments on this blog and posts on social networks are not investment recommendation, are provided solely for informational purposes, and do not constitute an offer or solicitation to buy or sell any securities. The opinions expressed on the blog are Petar Posledovich's. Petar Posledovich does not guarantee the accuracy of the information presented on this blog and social networks. The information presented is "as is". The blog is stocks analysis and valuation, Bitcoin, Cryptocurrencies, Artificial Intelligence, AI, deep-learning focused. Independent, unbiased AI insights. Petar Vladimirov Posledovich is not liable for any investment losses incurred by reading and interpreting blog posts on this blog and posts on social networks. Conflicts of interest: I may possess some of the securities, currencies or their derivatives mentioned in the blog post and posts on social networks! The blog is property of Wolfteam Ltd. www.wolfteamedge.com Respectfully yours, Petar Posledovich

Tuesday, September 26, 2023

AbbVie Valuation!

 

AbbVie Inc. the American pharmaceutical company is undervalued, according to Wolfteam Ltd.

AbbVie with 58.05 billion USD revenue, growing at 3.30 % and 20.39 % net profit margin for the calendar 2022 has an intrinsic worth of 220 billion USD, compared with AbbVie's current market capitalization of 272.96 billion USD.

The market seems to imply too high revenue growth and too high and stable profitability for AbbVie Inc.

AbbVie's dividend of 3.83 % is a very good advantage for AbbVie, though.

All in all, according to Wolfteam Ltd.'s estimates of comparable and earnings and revenue projections, AbbVie is overvalued.

Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)